Date Filed | Type | Description |
07/03/2023 |
4
| Russell Angus C. (Director) has filed a Form 4 on Lineage Cell Therapeutics, Inc.
Txns:
| Granted 50,000 options to buy
@ $1.41, valued at
$70.5k
|
|
05/05/2023 |
4
| Russell Angus C. (Director) has filed a Form 4 on Revance Therapeutics, Inc.
Txns:
| Granted 3,534 shares
@ $0 Granted 5,915 options to buy
@ $33.61, valued at
$198.8k
|
|
10/03/2022 |
4
| Russell Angus C. (Director) has filed a Form 4 on TherapeuticsMD, Inc.
Txns:
| Granted 5,000 restricted stock units
@ $0 |
|
08/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/13/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
05/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/15/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/12/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/30/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
11/16/2020 |
4
| Russell Angus C. (Director) has filed a Form 4 on Mallinckrodt plc
Txns:
| Sold 51,789 shares
@ $0.1287, valued at
$6.7k
|
|
07/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/19/2020 |
4
| Russell Angus C. (Director) has filed a Form 4 on TherapeuticsMD, Inc.
Txns:
| Granted 96,864 restricted stock units
@ $0 |
|
05/15/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/15/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/26/2019 |
4
| Russell Angus C. (Director) has filed a Form 4 on TherapeuticsMD, Inc.
Txns:
| Bought 10,000 shares
@ $2.77, valued at
$27.7k
|
|
08/15/2019 |
4
| Russell Angus C. (Director) has filed a Form 4 on TherapeuticsMD, Inc.
Txns:
| Bought 25,000 shares
@ $2.76, valued at
$69k
Bought 10,000 shares
@ $2.99, valued at
$29.9k
|
|
07/03/2019 |
4
| Russell Angus C. (Director) has filed a Form 4 on BIOTIME INC
Txns:
| Granted 40,000 options to buy
@ $1.03, valued at
$41.2k
|
|
06/24/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/17/2019 |
4
| Russell Angus C. (Director) has filed a Form 4 on Mallinckrodt plc
Txns:
| Paid exercise price by delivering 11,764 shares
@ $15.21, valued at
$178.9k
Granted 26,759 shares
@ $0 |
|
05/10/2019 |
4
| Russell Angus C. (Director) has filed a Form 4 on Revance Therapeutics, Inc.
Txns:
| Granted 4,500 shares
@ $0 Granted 9,000 options to buy
@ $12.82, valued at
$115.4k
|
|
07/05/2018 |
4
| Russell Angus C. (Director) has filed a Form 4 on TherapeuticsMD, Inc.
Txns:
| Granted 50,000 options to buy
@ $6.35, valued at
$317.5k
|
|
07/03/2018 |
4
| Russell Angus C. (Director) has filed a Form 4 on BIOTIME INC
Txns:
| Granted 40,000 options to buy
@ $2.06, valued at
$82.4k
|
|
05/18/2018 |
4
| Russell Angus C. (Director) has filed a Form 4 on Mallinckrodt plc
Txns:
| Granted 26,141 shares
@ $0 |
|
05/11/2018 |
4
| Russell Angus C. (Director) has filed a Form 4 on Revance Therapeutics, Inc.
Txns:
| Granted 3,000 shares
@ $0 Granted 6,000 options to buy
@ $29.15, valued at
$174.9k
|
|
03/05/2018 |
4
| Russell Angus C. (Director) has filed a Form 4 on Mallinckrodt plc
Txns:
| Paid exercise price by delivering 2,576 shares
@ $15.68, valued at
$40.4k
|
|
10/03/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
06/23/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
05/12/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
|